Lecanemab in Early Alzheimer’s Disease von van Dyck, Christopher H., Swanson, Chad J., Aisen, Paul, Bateman, Randall J., Chen, Christopher, Gee, Michelle, Kanekiyo, Michio, Li, David, Reyderman, Larisa, Cohen, Sharon, Froelich, Lutz, Katayama, Sadao, Sabbagh, Marwan, Vellas, Bruno, Watson, David, Dhadda, Shobha, Irizarry, Michael, Kramer, Lynn D., Iwatsubo, Takeshi

Volltext

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody von Swanson, Chad J, Zhang, Yong, Dhadda, Shobha, Wang, Jinping, Kaplow, June, Lai, Robert Y K, Lannfelt, Lars, Bradley, Heather, Rabe, Martin, Koyama, Akihiko, Reyderman, Larisa, Berry, Donald A, Berry, Scott, Gordon, Robert, Kramer, Lynn D, Cummings, Jeffrey L

Volltext

Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 pro... von McDade, Eric, Cummings, Jeffrey L, Dhadda, Shobha, Swanson, Chad J, Reyderman, Larisa, Kanekiyo, Michio, Koyama, Akihiko, Irizarry, Michael, Kramer, Lynn D, Bateman, Randall J

Volltext

The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease von Rafii, Michael S., Sperling, Reisa A., Donohue, Michael C., Zhou, Jin, Roberts, Claire, Irizarry, Michael C., Dhadda, Shobha, Sethuraman, Gopalan, Kramer, Lynn D, Swanson, Chad J, Li, David, Krause, Stephen, Rissman, Robert A., Walter, Sarah, Raman, Rema, Johnson, Keith A., Aisen, Paul S.

Volltext

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease von Honig, Lawrence S., Barakos, Jerome, Dhadda, Shobha, Kanekiyo, Michio, Reyderman, Larisa, Irizarry, Michael, Kramer, Lynn D., Swanson, Chad J., Sabbagh, Marwan

Volltext

Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies von Steinhoff, Bernhard J., Ben‐Menachem, Elinor, Ryvlin, Philippe, Shorvon, Simon, Kramer, Lynn, Satlin, Andrew, Squillacote, David, Yang, Haichen, Zhu, Jin, Laurenza, Antonio

Volltext

Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations von Dworkin, Robert H, Turk, Dennis C, Wyrwich, Kathleen W, Beaton, Dorcas, Cleeland, Charles S, Farrar, John T, Haythornthwaite, Jennifer A, Jensen, Mark P, Kerns, Robert D, Ader, Deborah N, Brandenburg, Nancy, Burke, Laurie B, Cella, David, Chandler, Julie, Cowan, Penny, Dimitrova, Rozalina, Dionne, Raymond, Hertz, Sharon, Jadad, Alejandro R, Katz, Nathaniel P, Kehlet, Henrik, Kramer, Lynn D, Manning, Donald C, McCormick, Cynthia, McDermott, Michael P, McQuay, Henry J, Patel, Sanjay, Porter, Linda, Quessy, Steve, Rappaport, Bob A, Rauschkolb, Christine, Revicki, Dennis A, Rothman, Margaret, Schmader, Kenneth E, Stacey, Brett R, Stauffer, Joseph W, von Stein, Thorsten, White, Richard E, Witter, James, Zavisic, Stojan

Volltext

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease von Dhadda, Shobha, Kanekiyo, Michio, Li, David, Swanson, Chad J, Irizarry, Michael, Berry, Scott, Kramer, Lynn D, Berry, Donald A

Volltext

Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease von Devanarayan, Viswanath, Doherty, Thomas, Charil, Arnaud, Sachdev, Pallavi, Ye, Yuanqing, Murali, Leema Krishna, Llano, Daniel A., Zhou, Jin, Reyderman, Larisa, Hampel, Harald, Kramer, Lynn D., Dhadda, Shobha, Irizarry, Michael C.

Volltext

Perampanel for adjunctive treatment of partial‐onset seizures: A pooled dose–response analysis of phase III studies von Kramer, Lynn D., Satlin, Andrew, Krauss, Gregory L., French, Jacqueline, Perucca, Emilio, Ben‐Menachem, Elinor, Kwan, Patrick, Shih, Jerry J., Laurenza, Antonio, Yang, Haichen, Zhu, Jin, Squillacote, David

Volltext

Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer's disease von Devanarayan, Viswanath, Charil, Arnaud, Horie, Kanta, Doherty, Thomas, Llano, Daniel A, Andreozzi, Erica, Sachdev, Pallavi, Ye, Yuanqing, Murali, Leema Krishna, Zhou, Jin, Reyderman, Larisa, Hampel, Harald, Kramer, Lynn D, Dhadda, Shobha, Irizarry, Michael C

Volltext

Updated safety results from phase 3 lecanemab study in early Alzheimer's disease von Honig, Lawrence S, Sabbagh, Marwan N, van Dyck, Christopher H, Sperling, Reisa A, Hersch, Steven, Matta, Andre, Giorgi, Luigi, Gee, Michelle, Kanekiyo, Michio, Li, David, Purcell, Derk, Dhadda, Shobha, Irizarry, Michael, Kramer, Lynn

Volltext

Core outcome domains for chronic pain clinical trials: IMMPACT recommendations von Turk, Dennis C, Dworkin, Robert H, Allen, Robert R, Bellamy, Nicholas, Brandenburg, Nancy, Carr, Daniel B, Cleeland, Charles, Dionne, Raymond, Farrar, John T, Galer, Bradley S, Hewitt, David J, Jadad, Alejandro R, Katz, Nathaniel P, Kramer, Lynn D, Manning, Donald C, McCormick, Cynthia G, McDermott, Michael P, McGrath, Patrick, Quessy, Steve, Rappaport, Bob A, Robinson, James P, Royal, Mike A, Simon, Lee, Stauffer, Joseph W, Stein, Wendy, Tollett, Jane, Witter, James

Volltext

Alzheimer's disease pathology in the neocortex and hippocampus of the western lowland gorilla (Gorilla gorilla gorilla) von Perez, Sylvia E., Raghanti, Mary Ann, Hof, Patrick R., Kramer, Lynn, Ikonomovic, Milos D., Lacor, Pascale N., Erwin, Joseph M., Sherwood, Chet C., Mufson, Elliott J.

Volltext

Plasma pTau181 enhances the prediction of future clinical decline in amyloid‐positive mild cognitive impairment von Devanarayan, Viswanath, Llano, Daniel A., Hu, Yan Helen, Hampel, Harald, Kramer, Lynn, Dhadda, Shobha, Irizarry, Michael

Volltext

Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial von Berry, Donald A, Dhadda, Shobha, Kanekiyo, Michio, Li, David, Swanson, Chad J, Irizarry, Michael, Kramer, Lynn D, Berry, Scott M

Volltext

Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer's disease von Honig, Lawrence S, Sabbagh, Marwan N, van Dyck, Christopher H, Sperling, Reisa A, Hersch, Steven, Matta, Andre, Giorgi, Luigi, Gee, Michelle, Kanekiyo, Michio, Li, David, Purcell, Derk, Dhadda, Shobha, Irizarry, Michael, Kramer, Lynn

Volltext

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody von Swanson, Chad J, Zhang, Yong, Dhadda, Shobha, Wang, Jinping, Kaplow, June, Lai, Robert Y K, Lannfelt, Lars, Bradley, Heather, Rabe, Martin, Koyama, Akihiko, Reyderman, Larisa, Berry, Donald A, Berry, Scott, Gordon, Robert, Kramer, Lynn D, Cummings, Jeffrey L

Volltext

Core outcome measures for chronic pain clinical trials: IMMPACT recommendations von Dworkin, Robert H., Turk, Dennis C., Farrar, John T., Haythornthwaite, Jennifer A., Jensen, Mark P., Katz, Nathaniel P., Kerns, Robert D., Stucki, Gerold, Allen, Robert R., Bellamy, Nicholas, Carr, Daniel B., Chandler, Julie, Cowan, Penney, Dionne, Raymond, Galer, Bradley S., Hertz, Sharon, Jadad, Alejandro R., Kramer, Lynn D., Manning, Donald C., Martin, Susan, McCormick, Cynthia G., McDermott, Michael P., McGrath, Patrick, Quessy, Steve, Rappaport, Bob A., Robbins, Wendye, Robinson, James P., Rothman, Margaret, Royal, Mike A., Simon, Lee, Stauffer, Joseph W., Stein, Wendy, Tollett, Jane, Wernicke, Joachim, Witter, James

Volltext

The β-Secretase BACE1 in Alzheimer’s Disease von Hampel, Harald, Vassar, Robert, De Strooper, Bart, Hardy, John, Willem, Michael, Singh, Neeraj, Zhou, John, Yan, Riqiang, Vanmechelen, Eugeen, De Vos, Ann, Nisticò, Robert, Corbo, Massimo, Imbimbo, Bruno Pietro, Streffer, Johannes, Voytyuk, Iryna, Timmers, Maarten, Tahami Monfared, Amir Abbas, Irizarry, Michael, Albala, Bruce, Koyama, Akihiko, Watanabe, Naoto, Kimura, Teiji, Yarenis, Lisa, Lista, Simone, Kramer, Lynn, Vergallo, Andrea

Volltext